Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer

Advances in Cancer Research

Volumn 123, Issue , 2014, Pages 277-317

  Skandalis, Spyros S ^a   Gialeli, Chrisostomi ^a,b   Theocharis, Achilleas D ^a   Karamanos, Nikos K ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

Cancer; CD44; Drug delivery; Hyaluronan; Nanomedicine; Nanoparticle; Pharmacological targeting

Indexed keywords

ANTINEOPLASTIC AGENT; HERMES ANTIGEN; HYALURONIC ACID; LIGAND; NANOCARRIER; NANOPARTICLE; CD44 PROTEIN, HUMAN; DRUG CARRIER; PROTEIN BINDING;

ARTICLE; CANCER THERAPY; CELL SURVIVAL; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; TARGET CELL; TUMOR GROWTH; ANIMAL; CHEMISTRY; GENE THERAPY; METABOLISM; MOUSE; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; GENETIC THERAPY; HUMANS; HYALURONIC ACID; MICE; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84904877392     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800092-2.00011-3     Document Type: Chapter

References (197)

1. Ahrens T., Sleeman J.P., Schempp C.M., Howells N., Hofmann M., Ponta H., et al. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 2001, 20(26):3399-3408. 10.1038/sj.onc.1204435.
2. Akima K., Ito H., Iwata Y., Matsuo K., Watari N., Yanagi M., et al. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: Synthesis, characterization and antitumor activity. Journal of Drug Targeting 1996, 4(1):1-8. 10.3109/10611869609046255.
3. Alaniz L., Garcia M.G., Gallo-Rodriguez C., Agusti R., Sterin-Speziale N., Hajos S.E., et al. Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor. Glycobiology 2006, 16(5):359-367. 10.1093/glycob/cwj085.
4. Alijotas-Reig J. Recurrent urticarial vasculitis related to nonanimal hyaluronic acid skin filler injection. Dermatologic Surgery 2009, 35(Suppl. 1):395-397. discussion 397-398. 10.1111/j.1524-4725.2008.01049.x.
5. Alijotas-Reig J., Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: Clinical findings, long-term follow-up and review of the literature. Journal of the European Academy of Dermatology and Venereology 2008, 22(2):150-161. 10.1111/j.1468-3083.2007.02354.x.
6. Allison D.D., Grande-Allen K.J. Review. Hyaluronan: A powerful tissue engineering tool. Tissue Engineering 2006, 12(8):2131-2140. 10.1089/ten.2006.12.2131.
7. Amoozgar Z., Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology 2012, 4(2):219-233. 10.1002/wnan.1157.
8. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., et al. Hyaluronic acid-paclitaxel: Antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9(6):479-486.
9. Avin E., Haimovich J., Hollander N. Anti-idiotype × anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma. The Journal of Immunology 2004, 173(7):4736-4743.
10. Ayhan A., Tok E.C., Bildirici I., Ayhan A. Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecologic Oncology 2001, 80(3):355-358. 10.1006/gyno.2000.6014.
11. Bajaj G., Kim M.R., Mohammed S.I., Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. Journal of Controlled Release 2012, 158(3):386-392. 10.1016/j.jconrel.2011.12.001.
12. Bartolazzi A., Peach R., Aruffo A., Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. The Journal of Experimental Medicine 1994, 180(1):53-66.
13. Baumgartner G. The impact of extracellular matrix on chemoresistance of solid tumors-Experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Letters 1998, 131(1):1-2.
14. Beckenlehner K., Bannke S., Spruss T., Bernhardt G., Schonenberg H., Schiess W. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. Journal of Cancer Research and Clinical Oncology 1992, 118(8):591-596.
15. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjugate Chemistry 2003, 14(6):1122-1132. 10.1021/bc034125f.
16. Bernauer W., Thiel M.A., Kurrer M., Heiligenhaus A., Rentsch K.M., Schmitt A., et al. Corneal calcification following intensified treatment with sodium hyaluronate artificial tears. The British Journal of Ophthalmology 2006, 90(3):285-288. 10.1136/bjo.2005.082792.
17. Borjesson P.K., Postema E.J., Roos J.C., Colnot D.R., Marres H.A., van Schie M.H., et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clinical Cancer Research 2003, 9(10Pt. 2):3961S-3972S.
18. Bourguignon L.Y. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Seminars in Cancer Biology 2008, 18(4):251-259. 10.1016/j.semcancer.2008.03.007.
19. Bourguignon L.Y., Singleton P.A., Diedrich F., Stern R., Gilad E. CD44 interaction with Na+-H+exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. The Journal of Biological Chemistry 2004, 279(26):26991-27007. 10.1074/jbc.M311838200.
20. Bourguignon L.Y., Singleton P.A., Zhu H., Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. The Journal of Biological Chemistry 2002, 277(42):39703-39712. 10.1074/jbc.M204320200.
21. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. The Journal of Biological Chemistry 2000, 275(3):1829-1838.
22. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. The Journal of Biological Chemistry 2001, 276(10):7327-7336. 10.1074/jbc.M006498200.
23. Bourguignon L.Y., Zhu H., Shao L., Zhu D., Chen Y.W. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motility and the Cytoskeleton 1999, 43(4):269-287. 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5.
24. Breyer R., Hussein S., Radu D.L., Putz K.M., Gunia S., Hecker H., et al. Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. Journal of Neurosurgery 2000, 92(1):140-149. 10.3171/jns.2000.92.1.0140.
25. Castillo-Vico M.T., Checa-Vizcaino M.A., Paya-Panades A., Rueda-Garcia C., Carreras-Collado R. Periurethral granuloma following injection with dextranomer/hyaluronic acid copolymer for stress urinary incontinence. International Urogynecology Journal and Pelvic Floor Dysfunction 2007, 18(1):95-97. 10.1007/s00192-005-0049-7.
26. Charrad R.S., Li Y., Delpech B., Balitrand N., Clay D., Jasmin C., et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nature Medicine 1999, 5(6):669-676. 10.1038/9518.
27. Choi S.H., Takahashi K., Eto H., Yoon S.S., Tanabe K.K. CD44s expression in human colon carcinomas influences growth of liver metastases. International Journal of Cancer 2000, 85(4):523-526.
28. Choi K.Y., Yoon H.Y., Kim J.H., Bae S.M., Park R.W., Kang Y.M., et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5(11):8591-8599. 10.1021/nn202070n.
29. Cichy J., Pure E. The liberation of CD44. The Journal of Cell Biology 2003, 161(5):839-843. 10.1083/jcb.200302098.
30. Colnot D.R., Roos J.C., de Bree R., Wilhelm A.J., Kummer J.A., Hanft G., et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunology, Immunotherapy 2003, 52(9):576-582. 10.1007/s00262-003-0396-5.
31. Colone M., Calcabrini A., Toccacieli L., Bozzuto G., Stringaro A., Gentile M., et al. The multidrug transporter P-glycoprotein: A mediator of melanoma invasion?. The Journal of Investigative Dermatology 2008, 128(4):957-971. 10.1038/sj.jid.5701082.
32. Coradini D., Pellizzaro C., Abolafio G., Bosco M., Scarlata I., Cantoni S., et al. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Investigational New Drugs 2004, 22(3):207-217. 10.1023/B:DRUG.0000026247.72656.8a.
33. Coradini D., Zorzet S., Rossin R., Scarlata I., Pellizzaro C., Turrin C., et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clinical Cancer Research 2004, 10(14):4822-4830. 10.1158/1078-0432.CCR-04-0349.
34. Cordo Russo R.I., Garcia M.G., Alaniz L., Blanco G., Alvarez E., Hajos S.E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. International Journal of Cancer 2008, 122(5):1012-1018. 10.1002/ijc.23122.
35. Daley W.P., Peters S.B., Larsen M. Extracellular matrix dynamics in development and regenerative medicine. Journal of Cell Science 2008, 121(Pt. 3):255-264. 10.1242/jcs.006064.
36. Dall P., Herrmann I., Durst B., Stoff-Khalili M.A., Bauerschmitz G., Hanstein B., et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunology, Immunotherapy 2005, 54(1):51-60. 10.1007/s00262-004-0569-x.
37. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release 2010, 148(2):135-146. 10.1016/j.jconrel.2010.08.027.
38. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nature Reviews Drug Discovery 2008, 7(9):771-782. 10.1038/nrd2614.
39. Di Meo C., Panza L., Campo F., Capitani D., Mannina L., Banzato A., et al. Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". Macromolecular Bioscience 2008, 8(7):670-681. 10.1002/mabi.200700304.
40. Doh K.O., Yeo Y. Application of polysaccharides for surface modification of nanomedicines. Therapeutic Delivery 2012, 3(12):1447-1456. 10.4155/tde.12.105.
41. Du H., Chandaroy P., Hui S.W. Grafted poly-(ethylene glycol) on lipid surfaces inhibits protein adsorption and cell adhesion. Biochimica et Biophysica Acta 1997, 1326(2):236-248.
42. Eliaz R.E., Nir S., Szoka F.C. Interactions of hyaluronan-targeted liposomes with cultured cells: Modeling of binding and endocytosis. Methods in Enzymology 2004, 387:16-33. 10.1016/S0076-6879(04)87002-2.
43. Eliaz R.E., Szoka F.C. Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells. Cancer Research 2001, 61(6):2592-2601.
44. Evanko S.P., Tammi M.I., Tammi R.H., Wight T.N. Hyaluronan-dependent pericellular matrix. Advanced Drug Delivery Reviews 2007, 59(13):1351-1365. 10.1016/j.addr.2007.08.008.
45. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews 2011, 63(3):136-151. 10.1016/j.addr.2010.04.009.
46. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24(7):1121-1131.
47. Foekens J.A., Dall P., Klijn J.G., Skroch-Angel P., Claassen C.J., Look M.P., et al. Prognostic value of CD44 variant expression in primary breast cancer. International Journal of Cancer 1999, 84(3):209-215.
48. Ghatak S., Misra S., Toole B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. The Journal of Biological Chemistry 2002, 277(41):38013-38020. 10.1074/jbc.M202404200.
49. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS Journal 2011, 278(1):16-27. 10.1111/j.1742-4658.2010.07919.x.
50. Gilg A.G., Tye S.L., Tolliver L.B., Wheeler W.G., Visconti R.P., Duncan J.D., et al. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clinical Cancer Research 2008, 14(6):1804-1813. 10.1158/1078-0432.CCR-07-1228.
51. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263(5153):1600-1603.
52. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65(1):13-24.
53. Guo Y., Ma J., Wang J., Che X., Narula J., Bigby M., et al. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Research 1994, 54(6):1561-1565.
54. Han S.E., Kang H., Shim G.Y., Kim S.J., Choi H.G., Kim J., et al. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. Journal of Drug Targeting 2009, 17(2):123-132. 10.1080/10611860802472461.
55. Harada N., Mizoi T., Kinouchi M., Hoshi K., Ishii S., Shiiba K., et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. International Journal of Cancer 2001, 91(1):67-75.
56. Hascall V., Karamanos N. Regulatory roles of hyaluronan in health and disease. The FEBS Journal 2011, 278(9):1411. 10.1111/j.1742-4658.2011.08068.x.
57. Hatakeyama H., Akita H., Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Advanced Drug Delivery Reviews 2011, 63(3):152-160. 10.1016/j.addr.2010.09.001.
58. Hathcock K.S., Hirano H., Murakami S., Hodes R.J. CD44 expression on activated B cells. Differential capacity for CD44-dependent binding to hyaluronic acid. The Journal of Immunology 1993, 151(12):6712-6722.
59. Hayes G.M., Carpenito C., Davis P.D., Dougherty S.T., Dirks J.F., Dougherty G.J. Alternative splicing as a novel of means of regulating the expression of therapeutic genes. Cancer Gene Therapy 2002, 9(2):133-141. 10.1038/sj.cgt.7700427.
60. Hayes G.M., Dougherty S.T., Davis P.D., Dougherty G.J. Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression. Cancer Gene Therapy 2004, 11(12):797-807. 10.1038/sj.cgt.7700759.
61. He Q., Lesley J., Hyman R., Ishihara K., Kincade P.W. Molecular isoforms of murine CD44 and evidence that the membrane proximal domain is not critical for hyaluronate recognition. The Journal of Cell Biology 1992, 119(6):1711-1719.
62. Hekele A., Dall P., Moritz D., Wels W., Groner B., Herrlich P., et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. International Journal of Cancer 1996, 68(2):232-238. 10.1002/(SICI)1097-0215(19961009)68:2<232::AID-IJC16>3.0.CO;2-C.
63. Heldin P., Karousou E., Bernert B., Porsch H., Nishitsuka K., Skandalis S.S. Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connective Tissue Research 2008, 49(3):215-218. 10.1080/03008200802143323.
64. Herold-Mende C., Seiter S., Born A.I., Patzelt E., Schupp M., Zoller J., et al. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. The Journal of Pathology 1996, 179(1):66-73. 10.1002/(SICI)1096-9896(199605)179:1<66::AID-PATH544>3.0.CO;2-5.
65. Herrera-Gayol A., Jothy S. Effect of hyaluronan on xenotransplanted breast cancer. Experimental and Molecular Pathology 2002, 72(3):179-185. 10.1006/exmp.2002.2437.
66. Hodge-Dufour J., Noble P.W., Horton M.R., Bao C., Wysoka M., Burdick M.D., et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. The Journal of Immunology 1997, 159(5):2492-2500.
67. Hong R.L., Huang C.J., Tseng Y.L., Pang V.F., Chen S.T., Liu J.J., et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial?. Clinical Cancer Research 1999, 5(11):3645-3652.
68. Hosono K., Nishida Y., Knudson W., Knudson C.B., Naruse T., Suzuki Y., et al. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. The American Journal of Pathology 2007, 171(1):274-286. 10.2353/ajpath.2007.060828.
69. Huxley-Jones J., Foord S.M., Barnes M.R. Drug discovery in the extracellular matrix. Drug Discovery Today 2008, 13(15-16):685-694. 10.1016/j.drudis.2008.05.005.
70. Iozzo R.V., Karamanos N. Proteoglycans in health and disease: Emerging concepts and future directions. The FEBS Journal 2010, 277(19):3863. 10.1111/j.1742-4658.2010.07796.x.
71. Ishida T. Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma. Surgery Today 2000, 30(1):28-32.
72. Ito T., Iida-Tanaka N., Niidome T., Kawano T., Kubo K., Yoshikawa K., et al. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: Protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. Journal of Controlled Release 2006, 112(3):382-388. 10.1016/j.jconrel.2006.03.013.
73. Jacobson A., Rahmanian M., Rubin K., Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. International Journal of Cancer 2002, 102(3):212-219. 10.1002/ijc.10683.
74. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nature Reviews. Clinical Oncology 2010, 7(11):653-664. 10.1038/nrclinonc.2010.139.
75. Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: Potential targets in pharmacotherapy. Pharmacological Reviews 2009, 61(2):198-223. 10.1124/pr.109.001289.
76. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Medicine 2005, 11(11):1173-1179. 10.1038/nm1315.
77. Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annual Review of Cell and Developmental Biology 2007, 23:435-461. 10.1146/annurev.cellbio.23.090506.123337.
78. Jiang G., Park K., Kim J., Kim K.S., Oh E.J., Kang H., et al. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 2008, 89(7):635-642. 10.1002/bip.20978.
79. Kao Y.J., Juliano R.L. Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochimica et Biophysica Acta 1981, 677(3-4):453-461.
80. Karamanos N.K., Tzanakakis G.N. Glycosaminoglycans: From "cellular glue" to novel therapeutical agents. Current Opinion in Pharmacology 2012, 12(2):220-222. 10.1016/j.coph.2011.12.003.
81. Karousou E., Kamiryo M., Skandalis S.S., Ruusala A., Asteriou T., Passi A., et al. The activity of hyaluronan synthase 2 is regulated by dimerization and ubiquitination. The Journal of Biological Chemistry 2010, 285(31):23647-23654. 10.1074/jbc.M110.127050.
82. Katoh S., Zheng Z., Oritani K., Shimozato T., Kincade P.W. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. The Journal of Experimental Medicine 1995, 182(2):419-429.
83. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Letters 1990, 268(1):235-237.
84. Klocker J., Sabitzer H., Raunik W., Wieser S., Schumer J. Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Letters 1998, 131(1):113-115.
85. Knudson W., Chow G., Knudson C.B. CD44-mediated uptake and degradation of hyaluronan. Matrix Biology 2002, 21(1):15-23.
86. Kozlova I., Ruusala A., Voytyuk O., Skandalis S.S., Heldin P. IQGAP1 regulates hyaluronan-mediated fibroblast motility and proliferation. Cellular Signalling 2012, 24(9):1856-1862. 10.1016/j.cellsig.2012.05.013.
87. Kursa M., Walker G.F., Roessler V., Ogris M., Roedl W., Kircheis R., et al. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjugate Chemistry 2003, 14(1):222-231. 10.1021/bc0256087.
88. Landesman-Milo D., Goldsmith M., Leviatan Ben-Arye S., Witenberg B., Brown E., Leibovitch S., et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Letters 2013, 334(2):221-227. 10.1016/j.canlet.2012.08.024.
89. Lee S.W., Yun M.H., Jeong S.W., In C.H., Kim J.Y., Seo M.H., et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. Journal of Controlled Release 2011, 155(2):262-271. 10.1016/j.jconrel.2011.06.012.
90. Lehtinen J., Magarkar A., Stepniewski M., Hakola S., Bergman M., Rog T., et al. Analysis of cause of failure of new targeting peptide in PEGylated liposome: Molecular modeling as rational design tool for nanomedicine. European Journal of Pharmaceutical Sciences 2012, 46(3):121-130. 10.1016/j.ejps.2012.02.009.
91. Lemarchand C., Gref R., Couvreur P. Polysaccharide-decorated nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2004, 58(2):327-341. 10.1016/j.ejpb.2004.02.016.
92. Lesley J., English N., Charles C., Hyman R. The role of the CD44 cytoplasmic and transmembrane domains in constitutive and inducible hyaluronan binding. European Journal of Immunology 2000, 30(1):245-253. 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.0.CO;2-X.
93. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. The Journal of Biological Chemistry 2000, 275(35):26967-26975. 10.1074/jbc.M002527200.
94. Lesley J., He Q., Miyake K., Hamann A., Hyman R., Kincade P.W. Requirements for hyaluronic acid binding by CD44: A role for the cytoplasmic domain and activation by antibody. The Journal of Experimental Medicine 1992, 175(1):257-266.
95. Lesley J., Howes N., Perschl A., Hyman R. Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response. The Journal of Experimental Medicine 1994, 180(1):383-387.
96. Lesley J., Hyman R. CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells. European Journal of Immunology 1992, 22(10):2719-2723. 10.1002/eji.1830221036.
97. Li L., Heldin C.H., Heldin P. Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. The Journal of Biological Chemistry 2006, 281(36):26512-26519. 10.1074/jbc.M605607200.
98. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Molecular Pharmaceutics 2008, 5(4):496-504. 10.1021/mp800049w.
99. Li J., Huo M., Wang J., Zhou J., Mohammad J.M., Zhang Y., et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012, 33(7):2310-2320. 10.1016/j.biomaterials.2011.11.022.
100. Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Advanced Drug Delivery Reviews 2008, 60(15):1650-1662. 10.1016/j.addr.2008.09.001.
101. Luo Y., Bernshaw N.J., Lu Z.R., Kopecek J., Prestwich G.D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharmaceutical Research 2002, 19(4):396-402.
102. Luo Y., Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chemistry 1999, 10(5):755-763.
103. Luo Y., Ziebell M.R., Prestwich G.D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1(2):208-218.
104. Mackay C.R., Terpe H.J., Stauder R., Marston W.L., Stark H., Gunthert U. Expression and modulation of CD44 variant isoforms in humans. The Journal of Cell Biology 1994, 124(1-2):71-82.
105. Marhaba R., Zoller M. CD44 in cancer progression: Adhesion, migration and growth regulation. Journal of Molecular Histology 2004, 35(3):211-231.
106. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research 1986, 46(12 Pt. 1):6387-6392.
107. McKee C.M., Lowenstein C.J., Horton M.R., Wu J., Bao C., Chin B.Y., et al. Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappaB-dependent mechanism. The Journal of Biological Chemistry 1997, 272(12):8013-8018.
108. McKee C.M., Penno M.B., Cowman M., Burdick M.D., Strieter R.M., Bao C., et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. The Journal of Clinical Investigation 1996, 98(10):2403-2413. 10.1172/JCI119054.
109. Meo C.D., Panza L., Capitani D., Mannina L., Banzato A., Rondina M., et al. Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules 2007, 8(2):552-559. 10.1021/bm0607426.
110. Merzak A., Koocheckpour S., Pilkington G.J. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Research 1994, 54(15):3988-3992.
111. Miletti-Gonzalez K.E., Chen S., Muthukumaran N., Saglimbeni G.N., Wu X., Yang J., et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Research 2005, 65(15):6660-6667. 10.1158/0008-5472.CAN-04-3478.
112. Mishra S., Webster P., Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. European Journal of Cell Biology 2004, 83(3):97-111. 10.1078/0171-9335-00363.
113. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. The Journal of Biological Chemistry 2005, 280(21):20310-20315. 10.1074/jbc.M500737200.
114. Misra S., Ghatak S., Zoltan-Jones A., Toole B.P. Regulation of multidrug resistance in cancer cells by hyaluronan. The Journal of Biological Chemistry 2003, 278(28):25285-25288. 10.1074/jbc.C300173200.
115. Misra S., Hascall V.C., De Giovanni C., Markwald R.R., Ghatak S. Delivery of CD44 shRNA/nanoparticles within cancer cells: Perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. The Journal of Biological Chemistry 2009, 284(18):12432-12446. 10.1074/jbc.M806772200.
116. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. The FEBS Journal 2011, 278(9):1429-1443. 10.1111/j.1742-4658.2011.08071.x.
117. Misra S., Obeid L.M., Hannun Y.A., Minamisawa S., Berger F.G., Markwald R.R., et al. Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. The Journal of Biological Chemistry 2008, 283(21):14335-14344. 10.1074/jbc.M703811200.
118. Misra S., Toole B.P., Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. The Journal of Biological Chemistry 2006, 281(46):34936-34941. 10.1074/jbc.C600138200.
119. Mizrahy S., Raz S.R., Hasgaard M., Liu H., Soffer-Tsur N., Cohen K., et al. Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. Journal of Controlled Release 2011, 156(2):231-238. 10.1016/j.jconrel.2011.06.031.
120. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacological Reviews 2001, 53(2):283-318.
121. Mummert M.E. Immunologic roles of hyaluronan. Immunologic Research 2005, 31(3):189-206. 10.1385/IR:31:3:189.
122. Mummert M.E., Mummert D., Edelbaum D., Hui F., Matsue H., Takashima A. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. The Journal of Immunology 2002, 169(8):4322-4331.
123. Nagase H., Karamanos N. Metalloproteinases in health and disease: Challenges and the future prospects. The FEBS Journal 2011, 278(1):1.
124. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Critical Reviews in Clinical Laboratory Sciences 2002, 39(6):527-579. 10.1080/10408360290795574.
125. Naor D., Wallach-Dayan S.B., Zahalka M.A., Sionov R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Seminars in Cancer Biology 2008, 18(4):260-267. 10.1016/j.semcancer.2008.03.015.
126. Noulas A.V., Skandalis S.S., Feretis E., Theocharis D.A., Karamanos N.K. Variations in content and structure of glycosaminoglycans of the vitreous gel from different mammalian species. Biomedical Chromatography 2004, 18(7):457-461. 10.1002/bmc.336.
127. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. European Journal of Cancer 2010, 46(7):1271-1277. 10.1016/j.ejca.2010.02.024.
128. Papadas T.A., Stylianou M., Mastronikolis N.S., Papageorgakopoulou N., Skandalis S., Goumas P., et al. Alterations in the content and composition of glycosaminoglycans in human laryngeal carcinoma. Acta Oto-Laryngologica 2002, 122(3):330-337.
129. Park K., Hong S.W., Hur W., Lee M.Y., Yang J.A., Kim S.W., et al. Target specific systemic delivery of TGF-beta siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials 2011, 32(21):4951-4958. 10.1016/j.biomaterials.2011.03.044.
130. Patel H.M., Moghimi S.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-The concept of tissue specificity. Advanced Drug Delivery Reviews 1998, 32(1-2):45-60.
131. Paul C.P., Good P.D., Winer I., Engelke D.R. Effective expression of small interfering RNA in human cells. Nature Biotechnology 2002, 20(5):505-508. 10.1038/nbt0502-505.
132. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2007, 2(12):751-760. 10.1038/nnano.2007.387.
133. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. International Journal of Cancer 2004, 108(5):780-789. 10.1002/ijc.11615.
134. Peer D., Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004, 6(4):343-353. 10.1593/neo.03460.
135. Peterson R.M., Yu Q., Stamenkovic I., Toole B.P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. The American Journal of Pathology 2000, 156(6):2159-2167. 10.1016/S0002-9440(10)65086-9.
136. Platt V.M., Szoka F.C. Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Molecular Pharmaceutics 2008, 5(4):474-486. 10.1021/mp800024g.
137. Ponta H., Sherman L., Herrlich P.A. CD44: From adhesion molecules to signalling regulators. Nature Reviews. Molecular Cell Biology 2003, 4(1):33-45. 10.1038/nrm1004.
138. Pouyani T., Prestwich G.D. Functionalized derivatives of hyaluronic acid oligosaccharides: Drug carriers and novel biomaterials. Bioconjugate Chemistry 1994, 5(4):339-347.
139. Prestwich G.D. Engineering a clinically-useful matrix for cell therapy. Organogenesis 2008, 4(1):42-47.
140. Prestwich G.D., Kuo J.W. Chemically-modified HA for therapy and regenerative medicine. Current Pharmaceutical Biotechnology 2008, 9(4):242-245.
141. Radotra B., McCormick D. Glioma invasion in vitro is mediated by CD44-hyaluronan interactions. The Journal of Pathology 1997, 181(4):434-438. 10.1002/(SICI)1096-9896(199704)181:4<434::AID-PATH797>3.0.CO;2-S.
142. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 2003, 80(1-2):148-158.
143. Reeder J.A., Gotley D.C., Walsh M.D., Fawcett J., Antalis T.M. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Research 1998, 58(16):3719-3726.
144. Remaut K., Lucas B., Braeckmans K., Demeester J., De Smedt S.C. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. Journal of Controlled Release 2007, 117(2):256-266. 10.1016/j.jconrel.2006.10.029.
145. Rivkin I., Cohen K., Koffler J., Melikhov D., Peer D., Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010, 31(27):7106-7114. 10.1016/j.biomaterials.2010.05.067.
146. Rochman M., Moll J., Herrlich P., Wallach S.B., Nedvetzki S., Sionov R.V., et al. The CD44 receptor of lymphoma cells: Structure-function relationships and mechanism of activation. Cell Adhesion and Communication 2000, 7(4):331-347.
147. Rupp U., Schoendorf-Holland E., Eichbaum M., Schuetz F., Lauschner I., Schmidt P., et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: Final results of a phase I study. Anti-Cancer Drugs 2007, 18(4):477-485. 10.1097/CAD.0b013e32801403f4.
148. Sauter A., Kloft C., Gronau S., Bogeschdorfer F., Erhardt T., Golze W., et al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. International Journal of Oncology 2007, 30(4):927-935.
149. Seiter S., Arch R., Reber S., Komitowski D., Hofmann M., Ponta H., et al. Prevention of tumor metastasis formation by anti-variant CD44. The Journal of Experimental Medicine 1993, 177(2):443-455.
150. Shuster S., Frost G.I., Csoka A.B., Formby B., Stern R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. International Journal of Cancer 2002, 102(2):192-197. 10.1002/ijc.10668.
151. Skandalis S.S., Kozlova I., Engstrom U., Hellman U., Heldin P. Proteomic identification of CD44 interacting proteins. IUBMB Life 2010, 62(11):833-840. 10.1002/iub.392.
152. Skandalis S.S., Stylianou M., Vynios D.H., Papageorgakopoulou N., Theocharis D.A. The structural and compositional changes of glycosaminoglycans are closely associated with tissue type in human laryngeal cancer. Biochimie 2007, 89(12):1573-1580. 10.1016/j.biochi.2007.07.006.
153. Skandalis S.S., Theocharis A.D., Papageorgakopoulou N., Zagris N. Glycosaminoglycans in early chick embryo. International Journal of Developmental Biology 2003, 47(4):311-314.
154. Skelton T.P., Zeng C., Nocks A., Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. The Journal of Cell Biology 1998, 140(2):431-446.
155. Skotheim R.I., Nees M. Alternative splicing in cancer: Noise, functional, or systematic?. International Journal of Biochemistry and Cell Biology 2007, 39(7-8):1432-1449. 10.1016/j.biocel.2007.02.016.
156. Sleeman J., Rudy W., Hofmann M., Moll J., Herrlich P., Ponta H. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. The Journal of Cell Biology 1996, 135(4):1139-1150.
157. Slomiany M.G., Dai L., Bomar P.A., Knackstedt T.J., Kranc D.A., Tolliver L., et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Research 2009, 69(12):4992-4998. 10.1158/0008-5472.CAN-09-0143.
158. Slomiany M.G., Grass G.D., Robertson A.D., Yang X.Y., Maria B.L., Beeson C., et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Research 2009, 69(4):1293-1301. 10.1158/0008-5472.CAN-08-2491.
159. Sneath R.J., Mangham D.C. The normal structure and function of CD44 and its role in neoplasia. Molecular Pathology 1998, 51(4):191-200.
160. Somasundaram C., Arch R., Matzku S., Zoller M. Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity. Cancer Immunology, Immunotherapy 1996, 42(6):343-350.
161. Song G., Liao X., Zhou L., Wu L., Feng Y., Han Z.C. HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leukemia Research 2004, 28(10):1089-1096. 10.1016/j.leukres.2004.02.005.
162. St Croix B., Man S., Kerbel R.S. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Letters 1998, 131(1):35-44.
163. Subramaniam V., Vincent I.R., Gilakjan M., Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Experimental and Molecular Pathology 2007, 83(3):332-340. 10.1016/j.yexmp.2007.08.013.
164. Sy M.S., Guo Y.J., Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. The Journal of Experimental Medicine 1992, 176(2):623-627.
165. Takei Y., Maruyama A., Ferdous A., Nishimura Y., Kawano S., Ikejima K., et al. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx. The FASEB Journal 2004, 18(6):699-701. 10.1096/fj.03-0494fje.
166. Tammi R.H., Kultti A., Kosma V.M., Pirinen R., Auvinen P., Tammi M.I. Hyaluronan in human tumors: Pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Seminars in Cancer Biology 2008, 18(4):288-295. 10.1016/j.semcancer.2008.03.005.
167. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. The Journal of Experimental Medicine 2002, 195(1):99-111.
168. Termeer C., Sleeman J.P., Simon J.C. Hyaluronan-Magic glue for the regulation of the immune response?. Trends in Immunology 2003, 24(3):112-114.
169. Thankamony S.P., Knudson W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. The Journal of Biological Chemistry 2006, 281(45):34601-34609. 10.1074/jbc.M601530200.
170. Theocharis D.A., Skandalis S.S., Noulas A.V., Papageorgakopoulou N., Theocharis A.D., Karamanos N.K. Hyaluronan and chondroitin sulfate proteoglycans in the supramolecular organization of the mammalian vitreous body. Connective Tissue Research 2008, 49(3):124-128. 10.1080/03008200802148496.
171. Theocharis A.D., Skandalis S.S., Tzanakakis G.N., Karamanos N.K. Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting. The FEBS Journal 2010, 277(19):3904-3923.
172. Theocharis A.D., Tsara M.E., Papageorgacopoulou N., Karavias D.D., Theocharis D.A. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochimica et Biophysica Acta 2000, 1502(2):201-206.
173. Theocharis A.D., Vynios D.H., Papageorgakopoulou N., Skandalis S.S., Theocharis D.A. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. International Journal of Biochemistry and Cell Biology 2003, 35(3):376-390.
174. Tijink B.M., Buter J., de Bree R., Giaccone G., Lang M.S., Staab A., et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clinical Cancer Research 2006, 12(20Pt. 1):6064-6072. 10.1158/1078-0432.CCR-06-0910.
175. Toole B.P. Hyaluronan in morphogenesis. Seminars in Cell and Developmental Biology 2001, 12(2):79-87. 10.1006/scdb.2000.0244.
176. Toole B.P. Hyaluronan: From extracellular glue to pericellular cue. Nature Reviews Cancer 2004, 4(7):528-539. 10.1038/nrc1391.
177. Toole B.P. Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clinical Cancer Research 2009, 15(24):7462-7468. 10.1158/1078-0432.CCR-09-0479.
178. Toole B.P., Slomiany M.G. Hyaluronan, CD44 and emmprin: Partners in cancer cell chemoresistance. Drug Resistance Updates 2008, 11(3):110-121. 10.1016/j.drup.2008.04.002.
179. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews 2011, 63(3):131-135. 10.1016/j.addr.2010.03.011.
180. Tsujimura S., Saito K., Kohno K., Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells. The Journal of Biological Chemistry 2006, 281(49):38089-38097. 10.1074/jbc.M601030200.
181. Turley E.A., Noble P.W., Bourguignon L.Y. Signaling properties of hyaluronan receptors. The Journal of Biological Chemistry 2002, 277(7):4589-4592. 10.1074/jbc.R100038200.
182. van Weering D.H., Baas P.D., Bos J.L. A PCR-based method for the analysis of human CD44 splice products. PCR Methods and Applications 1993, 3(2):100-106.
183. Verel I., Heider K.H., Siegmund M., Ostermann E., Patzelt E., Sproll M., et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. International Journal of Cancer 2002, 99(3):396-402. 10.1002/ijc.10369.
184. Vigetti D., Viola M., Karousou E., De Luca G., Passi A. Metabolic control of hyaluronan synthases. Matrix Biology 2014, 35:8-13. 10.1016/j.matbio.2013.10.002.
185. Vynios D.H., Theocharis D.A., Papageorgakopoulou N., Papadas T.A., Mastronikolis N.S., Goumas P.D., et al. Biochemical changes of extracellular proteoglycans in squamous cell laryngeal carcinoma. Connective Tissue Research 2008, 49(3):239-243. 10.1080/03008200802147662.
186. Wallach-Dayan S.B., Rubinstein A.M., Hand C., Breuer R., Naor D. DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Molecular Cancer Therapeutics 2008, 7(6):1615-1623. 10.1158/1535-7163.MCT-07-2383.
187. Weigel P.H., DeAngelis P.L. Hyaluronan synthases: A decade-plus of novel glycosyltransferases. The Journal of Biological Chemistry 2007, 282(51):36777-36781. 10.1074/jbc.R700036200.
188. Wu J.L., Liu C.G., Wang X.L., Huang Z.H. Preparation and characterization of nanoparticles based on histidine-hyaluronic acid conjugates as doxorubicin carriers. Journal of Materials Science: Materials in Medicine 2012, 23(8):1921-1929. 10.1007/s10856-012-4665-8.
189. Xu P., Quick G.K., Yeo Y. Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials 2009, 30(29):5834-5843. 10.1016/j.biomaterials.2009.07.012.
190. Yang R., Yan Z., Chen F., Hansson G.K., Kiessling R. Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-kappaB and protein kinase activity. Scandinavian Journal of Immunology 2002, 55(1):2-13.
191. Yerushalmi N., Arad A., Margalit R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Archives of Biochemistry and Biophysics 1994, 313(2):267-273. 10.1006/abbi.1994.1387.
192. Yuan Z.X., Zhang Z.R., Zhu D., Sun X., Gong T., Liu J., et al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Molecular Pharmaceutics 2009, 6(1):305-314. 10.1021/mp800078a.
193. Zahalka M.A., Okon E., Gosslar U., Holzmann B., Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. The Journal of Immunology 1995, 154(10):5345-5355.
194. Zardawi I.M. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee. The Journal of Bone and Joint Surgery 2003, 85-A(12):2484. author reply 2484-2485.
195. Zardawi I.M., Chan I. Synvisc perisynovitis. Pathology 2001, 33(4):519-520.
196. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. International Journal of Cancer 1998, 77(3):396-401.
197. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: Therapeutic applications and developments. Clinical Pharmacology and Therapeutics 2008, 83(5):761-769. 10.1038/sj.clpt.6100400.